|
- 积分
- 13
- 威望
- 13
- 包包
- 49
|
Targeted therapies that deliver the expected anti-tumor. E2 G5 A, g" U8 z- \
effects while mitigating the adverse effects are taking
! [, M5 a5 B; E/ t8 O& ]the cancer world by storm. The need for such therapies
' D9 y9 d; u2 Ein non-small cell lung cancer (NSCLC), where systemic5 h3 P$ z, V; ^- q& d; O! O
cytotoxic chemotherapies still remain the backbone of$ [, j- ?( V( O& C
management, is felt more than ever before. Runway3 J5 d0 l3 G8 g! o/ u9 X' r
success of immunotherapies such as Ipilimumab for: _! [: T- p, U6 n# n
melanoma has brought excitement among oncologists.7 S- C/ ~8 A D# o
Immune-based treatments are in various stages of
7 c2 S8 K. e' A- S9 x( v: Eevaluation for NSCLC as well. Immunotherapies using& ` t* p( `3 r
strategies of antigen based or cell based vaccines, and
' H+ X& f+ n9 o2 lblocking immune checkpoints are of substantial interest.; `- D' U5 y* ?- z8 m+ D
Meaningful clinical responses are yet to be reaped
, f( J9 O' |9 b: c6 i$ nfrom these new treatment modalities., K T# ?! d) I5 g- ^8 b
6 _; l+ m- V- Y$ ]. O( J+ b; V/ G
' {- e: b+ t W% a
Lung cancer is the leading cause of cancerdeath
- i3 B4 U* _6 {$ `0 \& f0 ~8 cworldwide. Majority of these patients have nonsmall- Z, W; G% H; ~; {
cell lung cancer (NSCLC). Traditional chemotherapy
( N' E5 B- }& j. n, o3 B, Tis limited by its high toxicity. Emerging data have
* [$ D5 D( Z; L/ |2 ddemonstrated promising outcome of immunotherapy in
! ^! H$ t% ^8 g8 x# D- @% x7 dNSCLC. This review delineated the rationale and potential- k' G. P( G! j+ I$ [
targets of cancer immunotherapy, with a summary
+ E. d9 g9 D# X4 t5 f& t, O: }3 Jof immunotherapeutic agents for treatment of NSCLC.
& x. S' H% a' v: HProtein/peptide-based and cell-based vaccines, as well
: y* n G8 x$ b8 o% }! p) V6 Gas immune checkpoint targeted agents such as Ipilimumab" p6 O {3 r; E# y: j
and PD-1 pathway inhibitors were discussed. In8 t) R! X- o( }- W
addition, we reviewed ongoing immunotherapy-based/ r+ j7 Q7 N* G
studies including several major phase Ⅱ/Ⅲ clinical trials,: E3 G% i* n2 i, a E
results of which will be available soon for incorporation
$ L2 r5 w. O; ?9 g( x: A5 Yinto clinical practice. |
|
发表于 2014-9-25 14:13
